Hi everyone,
This should be the last EITN! post for the 23-24 academic year. Thank you to everyone who has contributed, and to the others who let me know they follow this forum. It's great to know that EITN helps you keep up with the news, and that it helps you consolidate your learning in the programme.
Today's news is from The Guardian.
1. What is the study design?
2. What is the PICO?
3. What was the overall incidence of dementia?
4. The implication of this study is that SGLT-2 inhibitors reduce risk of dementia. But is it possible that DPP-4 inhibitors increase the risk of dementia? Just throwing this out there!
5. Are the findings generalisable outside the population of people aged 40-69 in South Korea on the national health insurance service? If not, why not?
6. Is the evidence now sufficient to declare that SGLT-2 prevents dementia? Is a trial required (and feasible/appropriate)?